News
Xenon Pharmaceuticals
XENE · NASDAQ
$36.27+$1.19 (+3.39%)TodayMarket closed ·
Prev close $35.08
Latest news
- Press releaseBusiness Wire
XENE Investors Have Opportunity to Join Xenon Pharmaceuticals Inc. Fraud Investigation with SBS Law
- Press releasePRNewswire
Xenon Pharmaceuticals Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Xenon Pharmaceuticals (XENE)
- Press releaseGlobe Newswire
Wolf Popper LLP Announces Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors
- NewsAvi Kapoor
Dow Falls Over 200 Points; Xenon Pharmaceuticals Shares Plunge
- NewsVandana Singh
Xenon Stock Reaction Is Overblown: Analyst
- NewsAvi Kapoor
US Stocks Mixed; Industrial Production Unchanged In August
- NewsAvi Kapoor
Xenon Pharmaceuticals, Steel Dynamics, Nucor And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
- News
Market-Moving News for September 18th
- NewsAvi Kapoor
Why Alaunos Therapeutics Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket
- NewsTanya Rawat
Xenon Pharmaceuticals (XENE) Shares Fall 25% After Hours: Here's Why
- NewsShivdeep Dhaliwal
Aethlon Medical, Oklo, CID HoldCo, Xenon Pharmaceuticals and Moderna: Why These 5 Stocks Are on Investors' Radars Today
- Press releaseGlobe Newswire
Xenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program
- Press releaseGlobe Newswire
Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026
- Press releaseGlobe Newswire
Xenon Reports Q2 2026 Financial Results and Provides Business Update
- NewsVandana Singh
Analyst Warns Biohaven's Lead Drug May Struggle To Stand Out
- Press releaseGlobe Newswire
Xenon Reports Q1 2026 Financial Results and Provides Business Update
- Press releaseGlobe Newswire
Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting
- Press releaseGlobe Newswire
Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting
- NewsAvi Kapoor
Crude Oil Rises Around 4%; Xenon Pharmaceuticals Shares Surge
- NewsVandana Singh
What's Going On With Biohaven Stock On Monday?
- NewsAvi Kapoor
Dow Tumbles Over 600 Points; Korn Ferry Posts Upbeat Earnings
- News
12 Health Care Stocks Moving In Monday's Pre-Market Session
- Press releaseGlobe Newswire
Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS)
- Press releaseGlobe Newswire
Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update
- NewsVandana Singh
Biohaven Misses The Mark In Depression Trial, Stock Falls
- News
Earnings Scheduled For November 3, 2025
- News
Insights into Xenon Pharmaceuticals's Upcoming Earnings
- News
Earnings Scheduled For August 11, 2025
- News
A Look Ahead: Xenon Pharmaceuticals's Earnings Forecast
- Press releaseBusiness Wire
Compass Pathways Appoints Justin Gover to Board of Directors
- NewsAvi Kapoor
Crude Oil Gains 3%; US Inflation Eases In April
- News
What to Expect from Xenon Pharmaceuticals's Earnings
- Press releaseGlobe Newswire
Xenon Reports Fourth Quarter & Full Year 2024 Financial Results and Business Update
- Press releaseGlobe Newswire
Xenon Reports Q3 2024 Financial Results and Business Update
- News
Earnings Preview: Xenon Pharmaceuticals
- Press releaseGlobe Newswire
Xenon Reports Q2 2024 Financial Results and Business Update
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.